Elotuzumab/Lenalidomide/Dexamethasone Maintenance After ASCT in Patients With MM: Preliminary Results From a Phase II Study

December 9-12, 2017; Atlanta, Georgia
Use of elotuzumab/lenalidomide/dexamethasone maintenance therapy following autologous stem cell transplantation in patients with multiple myeloma improved quality of response in 36% of patients in this preliminary analysis.
Format: Microsoft PowerPoint (.ppt)
File Size: 256 KB
Released: December 18, 2017


This activity is supported by educational grants from
Celgene Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics Inc.
Seattle Genetics
Takeda Oncology

Related Content

Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 20, 2022

On-demand webcast from ProCE and Clinical Care Options (CCO), Rebecca Gonzalez, PharmD, BCOP, and Bhavesh Shah, RPh, BCOP, discuss the management of relapsed/refractory multiple myeloma

Rebecca Gonzalez, PharmD, BCOP Bhavesh Shah, RPh, BCOP Pharmacists: 1.5 contact hours (0.15 CEUs) Released: June 15, 2022 Expired: June 14, 2023

DETERMINATION trial: addition of ASCT to VRd followed by lenalidomide maintenance until disease progression, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Maintenance carfilzomib/lenalidomide/dexamethasone associated with PFS improvement vs lenalidomide maintenance, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings